Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE1108.2552.7 (+4.99 %)

PREV CLOSE ( ) 1055.55

OPEN PRICE ( ) 1046.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8737

TODAY'S LOW / HIGH ( )1046.00 1146.15

52 WK LOW / HIGH ( )586.1 1359

NSE1104.9050.15 (+4.75 %)

PREV CLOSE( ) 1054.75

OPEN PRICE ( ) 1056.95

BID PRICE (QTY) 1104.90 (23)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 154325

TODAY'S LOW / HIGH( ) 1053.65 1147.10

52 WK LOW / HIGH ( )585.2 1360

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 06-11 2018

Management Info

Vivek Sharma - Chairman V Prasada Raju - Managing Director

Registered Office

Address 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri (East), Chakala Midc,
Mumbai,
Maharashtra-400093

Phone 022-61539999

Email info@suvenpharm.com

Website www.suvenpharm.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

15Jan Suven Pharmaceuticals informs about in
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

21Dec Suven Pharmaceuticals acquires 56% sta
Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, I..

07Dec Suven Pharmaceuticals informs about pr
Suven Pharmaceuticals has informed that it attached press release and in..

07Dec Suven Pharmaceuticals to acquire contr
Suven Pharmaceuticals is all set to acquire a controlling stake in NJ Bi..

09Sep Suven Pharmaceuticals’ arm gets EIR fr
Suven Pharmaceuticals’ Wholly Owned Subsidiary -- Casper Pharma’s formul..

Financials

Rs. in Millions

	QTR Sep 24	ANNUAL 24
Net Profit	763.3	3048.15
Gross Profit	1006.8	4087.74
Operating Profit	1144.4	4649.93
Net Sales	2360.6	10249.93

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 7441.40 (2.96%)	M.Cap ( in Cr)18603.50
Wockhardt (BSE) 1557.15 (10.00%)	M.Cap ( in Cr)25299.38
Medplus Health Servi (BSE) 787.20 (8.64%)	M.Cap ( in Cr)9422.30
Bajaj Healthcare (BSE) 690.80 (8.20%)	M.Cap ( in Cr)2181.77
Divi's Lab (BSE) 5622.30 (0.83%)	M.Cap ( in Cr)149254.40

Shareholding Pattern

	PROMOTERS	50.1%
	NON-INSTITUTION	22.37%
	MUTUAL FUNDS/UTI	13.15%
	FI/BANKS/INSURANCE	3.2%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	8.49
ITI Pharma & Health...	4.84
Mirae Asset Healthc...	3.54
LIC MF Healthcare F...	3.47
DSP Focus Fund-Reg(G)	2.97
UTI Healthcare Fund...	2.52
Tata Nifty MidSmall...	2.50

Risk Disclosures on Derivatives

Smart Quotes

SUVEN PHARMACEUTICALS LTD.